Company intelligence / Profile preview

GeneraMedix Inc.

Liberty Corner/Basking Ridge, New Jersey, United Stateszoominfo.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company developed and received FDA approval for Epoprostenol for Injection (1.5 mg/ml vial) on June 27, 2008, for the treatment of pulmonary hypertension[3]

Therapeutic areas: Cardiovascular
Modalities: Injectable products
Industry: Biotech

Drug pipeline

1 asset

epoprostenol

Commercial

Indications: Pulmonary arterial hypertension

Partnerships

Actelion Ltd. (sold improved formulation of epoprostenol sodium)[3]Bioniche Pharma (acquired seven products from GeneraMedix)[6]RoundTable Healthcare Partners (acquired several product lines)[7]

Beyond the preview

Go deeper on GeneraMedix Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneraMedix Inc..

Explore the full profile